Another Study Shows CBD Can Reduce Opioid Use

November 18, 2019 16:00:19

If you haven’t been living under a rock for the past few years, you have undoubtedly heard about cannabidiol (CBD). The cannabis extract has been having quite the magnificent run, with the CBD industry expected to be worth $20 billion by 2024. This growth is due to the compound’s insane potency and versatility as a medicine, with users saying CBD gave them relief from a variety of diseases ranging from high blood pressure to seizures in rare childhood epilepsies. Chronic pain relief is by far the most common issue CBD users seek to address, and a new study has produced further evidence that CBD can be useful as a pain reliever.

The study led by Dr. Alex Capano, Chief Science Officer of Ecofibre’s Ananda Health business in the United States, was looking to prove whether using CBD would reduce opioid use in the treatment of chronic pain. Ninety-seven chronic pain patients who had been using opioids for pain relief, some for decades, took part in the eight-week study. They were each provided with bottles containing 60 hemp-derived CBD soft gels (15 mg) at the start of…


About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.